Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Low frontal serotonin 2A receptor binding is a state marker for schizophrenia?

Rasmussen H, Frokjaer VG, Hilker RW, Madsen J, Anhøj S, Oranje B, Pinborg LH, Glenthøj B, Knudsen GM.

Eur Neuropsychopharmacol. 2016 Jul;26(7):1248-50. doi: 10.1016/j.euroneuro.2016.04.008. Epub 2016 May 11.

PMID:
27179966
2.

Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.

Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, Madsen J, Pinborg LH, Baaré W, Svarer C, Lublin H, Knudsen GM, Glenthoj B.

Arch Gen Psychiatry. 2010 Jan;67(1):9-16. doi: 10.1001/archgenpsychiatry.2009.176.

PMID:
20048218
3.

Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects.

Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J.

Eur Neuropsychopharmacol. 2013 Aug;23(8):852-64. doi: 10.1016/j.euroneuro.2012.10.006. Epub 2012 Nov 21.

4.

Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients.

Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baaré W, Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY.

Neuropsychopharmacology. 2008 Sep;33(10):2435-41. doi: 10.1038/sj.npp.1301656. Epub 2008 Feb 20.

5.
6.

Trait aggression and trait impulsivity are not related to frontal cortex 5-HT2A receptor binding in healthy individuals.

da Cunha-Bang S, Stenbæk DS, Holst K, Licht CL, Jensen PS, Frokjaer VG, Mortensen EL, Knudsen GM.

Psychiatry Res. 2013 May 30;212(2):125-31. doi: 10.1016/j.pscychresns.2012.09.007. Epub 2012 Nov 5.

PMID:
23137806
7.

Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding.

Frokjaer VG, Vinberg M, Erritzoe D, Baaré W, Holst KK, Mortensen EL, Arfan H, Madsen J, Jernigan TL, Kessing LV, Knudsen GM.

Neuropsychopharmacology. 2010 Apr;35(5):1129-37. doi: 10.1038/npp.2009.218. Epub 2009 Dec 30.

8.

Cognition-induced modulation of serotonin in the orbitofrontal cortex: a controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin.

Hautzel H, Müller HW, Herzog H, Grandt R.

Neuroimage. 2011 Oct 1;58(3):905-11. doi: 10.1016/j.neuroimage.2011.06.009. Epub 2011 Jun 17.

PMID:
21722741
9.

Brain dopamine d1 receptors in twins discordant for schizophrenia.

Hirvonen J, van Erp TG, Huttunen J, Aalto S, Någren K, Huttunen M, Lönnqvist J, Kaprio J, Cannon TD, Hietala J.

Am J Psychiatry. 2006 Oct;163(10):1747-53.

PMID:
17012685
10.

Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia.

Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, Coenen HH, Vogeley K, Falkai P, Zilles K, Maier W, Bauer A.

Anat Embryol (Berl). 2005 Dec;210(5-6):519-23.

PMID:
16187138
11.

The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined.

Pinborg LH, Arfan H, Haugbol S, Kyvik KO, Hjelmborg JV, Svarer C, Frokjaer VG, Paulson OB, Holm S, Knudsen GM.

Neuroimage. 2008 Apr 15;40(3):1175-80. doi: 10.1016/j.neuroimage.2007.09.019. Epub 2007 Sep 21.

PMID:
18291676
12.

Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder.

Frokjaer VG, Mortensen EL, Nielsen FA, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM.

Biol Psychiatry. 2008 Mar 15;63(6):569-76. Epub 2007 Sep 19.

PMID:
17884017
13.

Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia.

Hirvonen J, van Erp TG, Huttunen J, Aalto S, Någren K, Huttunen M, Lönnqvist J, Kaprio J, Hietala J, Cannon TD.

Arch Gen Psychiatry. 2005 Apr;62(4):371-8.

PMID:
15809404
14.

Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.

Lian J, Huang XF, Pai N, Deng C.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:62-8. doi: 10.1016/j.pnpbp.2013.08.005. Epub 2013 Aug 27.

PMID:
23994047
15.

5-HT2A receptor density is decreased in the at-risk mental state.

Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A.

Psychopharmacology (Berl). 2008 Jan;195(4):579-90. Epub 2007 Sep 27.

PMID:
17899021
16.

Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands.

Herth MM, Petersen IN, Hansen HD, Hansen M, Ettrup A, Jensen AA, Lehel S, Dyssegaard A, Gillings N, Knudsen GM, Kristensen JL.

Nucl Med Biol. 2016 Aug;43(8):455-62. doi: 10.1016/j.nucmedbio.2016.02.011. Epub 2016 Apr 19.

PMID:
27209485
17.

No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia.

Kouzmenko AP, Scaffidi A, Pereira AM, Hayes WL, Copolov DL, Dean B.

Hum Hered. 1999 Mar;49(2):103-5.

PMID:
10077731
18.

Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.

Nørbak-Emig H, Ebdrup BH, Fagerlund B, Svarer C, Rasmussen H, Friberg L, Allerup PN, Rostrup E, Pinborg LH, Glenthøj BY.

Int J Neuropsychopharmacol. 2016 Apr 29;19(5). pii: pyw006. doi: 10.1093/ijnp/pyw006. Print 2016 May.

19.

Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H.

Psychopharmacology (Berl). 2007 Feb;190(2):241-9. Epub 2006 Nov 17.

PMID:
17111172
20.

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baaré WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B.

Psychopharmacology (Berl). 2011 Feb;213(2-3):583-92. doi: 10.1007/s00213-010-1941-5. Epub 2010 Jul 8.

PMID:
20614105

Supplemental Content

Support Center